Letter to the EditorLetter to the editor: Comments on ‘A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica’
Section snippets
Author contributions
David Liew developed the initial manuscript and finalised for submission. All authors substantially contributed to revising the article, critically regarding important intellectual content, approving the final version and agreeing to be accountable for the integrity of the work.
Conflict of interest statement
None declared.
References (12)
- et al.
A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica
Eur J Cancer
(2018) - et al.
Polymyalgia rheumatica
Lancet
(2017) - et al.
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
Eur J Cancer
(2018) - et al.
2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism/American College of Rheumatology collaborative initiative
Ann Rheum Dis
(2015) - et al.
Rheumatic immune-related adverse events from cancer immunotherapy
Nat Rev Rheumatol
(2018) - et al.
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature [abstract]
Arthritis Rheumatol
(2018)
There are more references available in the full text version of this article.
Cited by (0)
© 2019 Elsevier Ltd. All rights reserved.